scholarly journals Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro

2016 ◽  
pp. 1909 ◽  
Author(s):  
Zhe Wang ◽  
Li Wang ◽  
Ren-ai Xu ◽  
Yun-yun Zhan ◽  
Cheng-ke Huang ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

scholarly journals Breast cancer: Role of pharmacogenetics in tamoxifen therapy

2016 ◽  
Vol 1 (1) ◽  
pp. 10
Author(s):  
Smriti Mishra ◽  
Manish Manish
Keyword(s):  
Breast Cancer ◽  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Clinical Outcome ◽  
Tamoxifen Therapy ◽  
Uridine Diphosphate ◽  
Cytochrome P450 2D6 ◽  
Cytochrome P450 3A ◽  
P450 2D6

<p><span>The role of pharmacogenetics in the personalization of tamoxifen therapy has relevance in the management of breast cancer. Since Tamoxifen is a pro-drug, genetic polymorphism in Phase I and Phase II drug metabolizing enzymes involved in the bioconversion of tamoxifen to therapeutically active metabolites is critical in determining therapeutic efficacy and adverse drug reactions of the therapy in breast cancer patients. In this review, the role of pharmacogenetics in the personalization of tamoxifen therapy has been discussed. Since, metabolism of tamoxifen by Cytochrome P450 2D6 is significant in determining the therapeutic efficacy of the drug, most of the clinical evidence on tamoxifen pharmacogenetics have been correlated with cytochrome p450 2D6 genetic polymorphism. However, there is discordance in the clinical data, and one of the reasons is the incomplete analysis of all the alleles of cytochrome p450 2D6. International Tamoxifen Pharmacogenomics Consortium has been formed to assess   the discordance. There are also clinical evidences associating genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome of tamoxifen therapy. However, associations of genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome in populations of different ethnicity are unexplored. Evidences on  the association of genetic polymorphisms and the clinical outcome have been summarized in the Table.  Since cost, statistically significant sample population size, labor and ethical issues are the major concerns of a pharmacogenetic investigation; the significance of bottom-up approach in pharmacogenetics has been discussed.</span></p>

Topological role of cytochrome P450 2D6 active site residues

2006 ◽  
Vol 447 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Robert A.B. van Waterschoot ◽  
Peter H.J. Keizers ◽  
Chris de Graaf ◽  
Nico P.E. Vermeulen ◽  
Richard A. Tschirret-Guth
Keyword(s):  
Cytochrome P450 ◽  
Active Site ◽  
Cytochrome P450 2D6 ◽  
Active Site Residues ◽  
P450 2D6

Effect of 24 Cytochrome P450 2D6 Variants Found in the Chinese Population on Atomoxetine Metabolism in vitro

Pharmacology ◽  
2015 ◽  
Vol 97 (1-2) ◽  
pp. 78-83 ◽  
Author(s):  
Bingqing Liang ◽  
Yunyun Zhan ◽  
Ying Wang ◽  
Ermin Gu ◽  
Dapeng Dai ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Chinese Population ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

Inhibition of Desipramine Hydroxylation (Cytochrome P450-2D6) in Vitro by Quinidine and by Viral Protease Inhibitors: Relation to Drug Interactions in Vivo

1998 ◽  
Vol 87 (10) ◽  
pp. 1184-1189 ◽  
Author(s):  
Lisa L. von Moltke ◽  
David J. Greenblatt ◽  
Su Xiang Duan ◽  
Johanna P. Daily ◽  
Jerold S. Harmatz ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Drug Interactions ◽  
Protease Inhibitors ◽  
Cytochrome P450 2D6 ◽  
Viral Protease ◽  
P450 2D6
Sign in / Sign up

Export Citation Format

Share Document